



MERCURY LABORATORIES LIMITED

Date: 25/07/2026

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Tower, 25th Floor
Dalal Street, Mumbai – 400 001

Scrip Code: 538964

Subject: Outcome of the Board Meeting held on July 25, 2026

Ref: Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

It is hereby informed that the Board of Directors at its meeting held today i.e. on Saturday, July 25, 2026 inter-alia, approved the unaudited financial results of the Company for the quarter ended on June 30, 2026. Accordingly, we enclose the following:

- i. Unaudited Financial Results for the quarter ended on June 30, 2026 and,
- ii. Limited Review Report on the unaudited financial results for the quarter ended on June 30, 2026 by the Statutory Auditors of the Company;

The Meeting commenced at 9:30 a.m (IST) and concluded at 11:33 a.m (IST)

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,
For Mercury Laboratories Limited



Rajendra Shah
Managing Director
DIN:00257253

Encl: As above

MERCURY LABORATORIES LIMITED

UNAUDITED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30, 2026

(₹ in lakhs)

Sr. No.	Particulars	QUARTER ENDED		YEAR ENDED	
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Revenue from Operations	1,596.32	2,044.24	1,813.54	7,593.67
2	Other Income	5.22	67.09	18.10	195.51
3	Total Income	1,601.54	2,111.33	1,831.64	7,789.18
4	Expenses				
	Cost of materials consumed	579.14	690.03	593.83	2,535.58
	Purchase of Traded Goods	65.01	75.24	33.78	227.60
	Changes in inventories of finished goods, work in progress and stock in trade	(34.83)	19.29	97.40	189.15
	Employee benefits expense	423.64	457.42	424.26	1,743.65
	Finance Costs	12.30	13.05	14.53	54.48
	Depreciation and Amortisation expenses	72.90	84.39	84.34	341.96
	Other Expenses	444.19	598.23	428.77	1,993.55
	Total Expenses	1,562.35	1,937.65	1,676.91	7,085.97
5	Profit Before Exceptional Items and Tax	39.19	173.68	154.73	703.21
6	Exceptional Item - Refer note no 3	-	-	-	(39.49)
7	Profit before Tax	39.19	173.68	154.73	663.72
8	Tax Expenses				
	a. Current Tax	13.00	0.47	48.00	166.13
	b. Deferred Tax	(3.59)	50.67	9.97	14.19
9	Net Profit after Tax	29.78	122.54	96.76	483.40
10	Other Comprehensive Income				
	i. Items that will not be reclassified to profit or loss remeasurement of the net defined benefit liability/ assets	3.12	9.99	0.20	12.47
	ii. Income tax relating to items that will not be reclassified to profit or loss	(0.78)	(2.52)	(0.05)	(3.14)
11	Total other comprehensive income, net of tax	2.34	7.47	0.15	9.33
12	Total comprehensive income for the period	32.12	130.01	96.91	492.73
13	Paid up equity share capital (face value of Rs.10/- each)	-	-	-	120.00
14	Other Equity	-	-	-	5687.65
15	Earning Per Share - Basic & Diluted * (In Rs.)	2.48	10.21	8.06	40.28
	* for the period only and not annualised				

By order of the Board of Directors
Mercury Laboratories Limited

Place: Vadodara
Date: July 25, 2026




Mr. Rajendra R Shah
Managing Director
DIN: 00257253

Head Office & Factory - 1 :
2/13-14, Gorwa Industrial Estate, Gorwa,
Vadodara - 390 016, Ph. : 0265 2477900 | 906 | 908
E-mail : mllbrd@mercurylabs.com

Factory - 2 :
Halol-Vadodara Road, Vill. : Jarod,
Vadodara - 391 510.
E-mail : mllbrd@mercurylabs.com

Regd. Office :
1st Floor 18, Shreeji Bhuvan, 51, Mangaldas Road,
Princess Street, Mumbai - 400 002. Ph. : 022 22015441.
Ph. : 022 66372841. E-mail : secretarial@mercurylabs.com

MERCURY LABORATORIES LIMITED

NOTES ON UNAUDITED FINANCIAL RESULTS:

1. The above Financial results for the quarter ended on June 30, 2026 were reviewed and recommended by the Audit Committee and thereafter approved by Board of Directors at their respective meetings held on July 25, 2026 at Vadodara.
2. The Statutory Auditors have performed a 'Limited Review' of the above financial results for the quarter ended on June 30, 2026
3. The financial results of the Company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms with Regulation 33 of SEBI (LODR), 2015 and SEBI Circular dated 05.07.2016.
4. The business of the Company fall under Single Segment i.e. "Pharmaceuticals Products".
5. Previous quarter's figure have been re grouped / re classified, wherever necessary to confirm to current period classification. The figures for the quarter ended March 31, 2026 are balancing figures between audited figures in respect of the full Financial year and unaudited published year to date figures upto the third quarter of respective Financial Year

Place: Vadodara
Date: 25/07/2026

By order of the Board of Directors
Mercury Laboratories Limited



Mr. Rajendra R Shah
Managing Director
DIN:00257253

Head Office & Factory - 1 :
2/13-14, Gorwa Industrial Estate, Gorwa,
Vadodara - 390 016, Ph. : 0265 2477900 | 906 | 908
E-mail : mllbrd@mercurylabs.com

Factory - 2 :
Halol-Vadodara Road, Vill. : Jarod,
Vadodara - 391 510.
E-mail : mllbrd@mercurylabs.com

Regd. Office :
1st Floor 18, Shreeji Bhuvan, 51, Mangaldas Road,
Princess Street, Mumbai - 400 002. Ph. : 022 22015441.
Ph. : 022 66372841. E-mail : secretarial@mercurylabs.com


Limited Review Report on the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026 pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015.

To,
The Board of Directors,
Mercury Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Mercury Laboratories Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement"), being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Vadodara
Date: 25th July, 2026



For Naresh & Co.
Chartered Accountants
FRN: 106928W

CA Abhijeet Dandekar
Partner
M. No. 108377

UDIN: 26108377CKIZQD3175